Navigation Links
NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
Date:3/19/2008

his is part of NicOx' strategy to maximize the commercial potential and economic value of naproxcinod, as NicOx owns the global development and marketing rights to this compound. Going forward, NicOx will be looking for co-commercialization partnerships for naproxcinod, with NicOx retaining certain commercialization rights in the U.S. and selected EU markets, in order to fully exploit the drug's commercial and strategic value and to aid the Company's planned transition to a fully integrated pharmaceutical business.

James Harrison, CEO of Archimica, declared: "We are very pleased to have this opportunity to apply our expertise to the manufacturing of naproxcinod and are excited by the clear potential of this innovative product. We look forward to continuing our work with the NicOx team, and leveraging our manufacturing experience to support their timely and successful launch of naproxcinod."

NicOx is developing naproxcinod in phase 3 clinical studies, which are designed to demonstrate that it is safe, well tolerated and effective for treating the signs and symptoms of osteoarthritis, in addition to having no detrimental effect on blood pressure, in contrast to existing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The final pivotal phase 3 trials are ongoing (the 302 and 303 studies) and the filing of a New Drug Application (NDA) for naproxcinod is projected for mid-2009.

About Archimica

Archimica is a privately held pharmaceutical fine chemicals company owned by TowerBrook Capital Partners and Aisling Capital Partners. Archimica combines first-class chemical manufacturing assets, technologies and process development with a history of pharmaceutical commercialization that stretches back over 40 years. With respect to new manufacturing projects, Archimica's strategy is focused on phase 2 and phase 3 clinical trial manufacturing opportunities for New Chemical Entities (NCEs) and this partnership with NicOx on naproxcinod is an important ex
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NicOx Opens U.S. Headquarters in New Jersey
2. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
3. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. Monsanto Company Signs Share Subscription Agreement With Devgen
8. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
9. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
10. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
11. Assay Designs(TM) Announces Additions to the Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... (PRWEB) March 25, 2015 An increase ... ingredients in all forms of food nutrients, regulatory changes ... a substantial rise in demand for natural astaxanthin over ... started to ramp up their capacities to satisfy the ... natural and synthetic source astaxanthin (used in nutraceuticals, aqua ...
(Date:3/25/2015)... March 25, 2015 Data from ... Mechanism of Action in Neuromuscular Diseases , ... Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of ... troponin activator tirasemtiv in the journal Neurotherapeutics. ... “Evidence of Effect” or hypothesis-generating clinical trial which ...
(Date:3/25/2015)... March 25, 2015 Researchers at ... nanoparticle technology that will enable broader and less ... diseases with a simple breath screen. The Minnesota-based ... U.S. Food and Drug Administration (FDA) approval process ... the innovative Nanoparticle Biomarker Tagging device. , Ancon ...
(Date:3/25/2015)...  The Technology Association of Georgia ... promotion and economic advancement of Georgia,s ... of its Top 40 Innovative Technology Companies in ... group at the 2015 Georgia Technology Summit (GTS) on ... TAG,S Top 40 Awards recognize Georgia ...
Breaking Biology Technology:Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 2Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 4
... carbon nanotubes more than doubles the growth rate of ... everything from lifesaving medications to sweeteners to dyes and ... to show that carbon nanotubes boost plant cell division ... . Mariya V. Khodakovskaya and colleagues explain that ...
... Ga., April 4, 2012  MiMedx Group, Inc. (OTCBB: MDXG), ... regenerative biomaterials and bioimplants processed from human amniotic membrane, ... revenue goal for the first quarter of 2012. The ... $3.6 million. The Company also reported ...
... SETAUKET, N.Y., April 4, 2012 Lixte Biotechnology Holdings, ... the United States Patent and Trademark Office for its ... homologs. Dr. John Kovach, founder and president ... certain types of skin lymphomas and many other HDACi ...
Cached Biology Technology:MiMedx Exceeds Revenue Goal for First Quarter of 2012 2Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 2Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor 3
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Research Institute scientists has taken a significant step toward answering ... RNA enzymes that can replicate themselves without the help of ... indefinitely. The work was published on Thursday, January ... edition of the journal Science . In the ...
... Calif., January 9, 2009 -- Researchers at the ... that search algorithms used in digital communications can ... led by Giovanni Paternostro, M.D., Ph.D., was published ... PLoS Computational Biology . Using the stack ...
... unveil a novel "two-stage, approach for developing new energy ... emissions and create a cleaner economy during a policy ... York Ave. N.W. in Washington, D.C. , ... Mellon, the University of Minnesota, The Vermont Law School ...
Cached Biology News:Scripps scientists develop first examples of RNA that replicates itself indefinitely 2Scripps scientists develop first examples of RNA that replicates itself indefinitely 3Scripps scientists develop first examples of RNA that replicates itself indefinitely 4Digital communication technology helps clear path to personalized therapies 2Carnegie Mellon to unveil new sequestration plan 2
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
... Model 440 incorporates four channels of sophisticated ... easy-to-use instrument. Each channel consists of a ... lowpass filter, a highpass filter, a line ... control knob sets the amplifier parameters and ...
... licensed, high throughput, water bath thermal cycler capable ... microplates. This equates to 9,216 reactions per run ... arm rapidly transfers a basket of plates between ... that are considerably faster than those of peltier ...
... is a four-channel general purpose laboratory amplifier. It ... sources which may have a large common-mode level ... a high gain/low noise amplifier, an input coupling ... offset control. A control knob sets the amplifier ...
Biology Products: